Accordingly, restoration of Treg function in RA patients treated with Infliximab has been traced back to an emerging and unusual CD62L− Treg population that after TNF blockade differentiates via TGFβ from CD4+CD25− cells of RA patients but not of healthy individuals (78). Here, SELL is linked to rheumatoid arthritis.